All In Biotech

Drug Trial Radar · NCT07703436

Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease

A Phase 2, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Participants With Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Mar 2027

Primary completion

Sep 2030

Study completion Mar 2032

Sponsor

Lead sponsor
Nuvation Bio Inc.Industry
Sponsor type
Industry
First posted
Jul 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will include up to 40 participants with Grade 2 or Grade 3 IDH1-mutant glioma who have undergone surgery and received vorasidenib as their only treatment, experienced radiographic disease progression on vorasidenib (confirmed by Blinded Independent Central Review \[BICR\] per modified Response Assessment in Neuro-Oncology \[RANO\] 2.0), and are not in need of immediate chemotherapy or radiotherapy.

Conditions

  • Grade 2 IDH1-mutant Glioma
  • Grade 3 IDH1-mutant Glioma
  • Glioma
  • IDH1-mutant Glioma
  • Oligodendroglioma
  • Oligodendroglioma IDH-1 Mutant and 1/p19q-codeleted
  • Astrocytoma IDH Mutant Grade 3
  • Astrocytoma IDH Mutant Grade 2

Interventions

  • SafusidenibDrug

    Safusidenib administered twice daily as a single agent orally on Days 1 to 28 of a 28-day cycle. Participants may continue treatment until disease progression or another reason for discontinuation occurs.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) per modified Response Assessment in Neuro-Oncology (RANO) 2.0 assessed by Blinded Independent Central Review (BICR)Time frame: From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • University of California, Los Angeles

    Los Angeles, California · Not yet recruiting

  • University of California, San Francisco

    San Francisco, California · Not yet recruiting

  • Yale University

    New Haven, Connecticut · Not yet recruiting

  • University of Miami Health

    Miami, Florida · Not yet recruiting

  • Indiana University

    Indianapolis, Indiana · Recruiting

  • LSU LCMC Health Cancer Center

    New Orleans, Louisiana · Not yet recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Not yet recruiting

  • Rutgers Cancer Institute

    New Brunswick, New Jersey · Not yet recruiting

  • NYU Langone Health

    New York, New York · Recruiting

  • Columbia University Medical Center

    New York, New York · Not yet recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Not yet recruiting

  • The Ohio State University Comprehensive Cancer Center

    Columbus, Ohio · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.